Table 1.
Patient Characteristics at Baseline
| Sunitinib (N = 63) | |||
|---|---|---|---|
| Characteristic | No. of Patients |
% | |
| Age, years | |||
| Median | 60 | ||
| Range | 33–86 | ||
| Sex | |||
| Male | 41 | 65 | |
| Female | 22 | 35 | |
| ECOG performance status | |||
| 0 | 28 | 4 | |
| 1 | 35 | 56 | |
| Smoking status | |||
| Ever | 50 | 79 | |
| Never | 10 | 16 | |
| Not known | 3 | 5 | |
| NSCLC histology | |||
| Adenocarcinoma | 40 | 64 | |
| Squamous cell carcinoma | 14 | 22 | |
| Bronchioloalveolar | 2 | 3 | |
| Large-cell carcinoma | 2 | 3 | |
| NSCLC NOS | 5 | 8 | |
| Disease stage | |||
| IIIB | 6 | 10 | |
| IV | 57 | 90 | |
| Metastatic sites | |||
| Lymph nodes | 39 | 62 | |
| Bone | 24 | 38 | |
| Pleural effusion | 15 | 24 | |
| Liver | 13 | 21 | |
| Soft tissue | 11 | 18 | |
| Adrenal gland | 7 | 11 | |
| Skin | 5 | 8 | |
| Peritoneal | 1 | 2 | |
| Other | 9 | 14 | |
| No. of prior systemic regimens | |||
| 1 | 25 | 40 | |
| 2 | 30 | 48 | |
| ≥ 3 | 8 | 13 | |
| No. of prior chemotherapy regimens | |||
| 1 | 37 | 59 | |
| 2 | 23 | 36 | |
| ≥ 3 | 3 | 5 | |
| Prior treatments | 63 | 100 | |
| Platinum agent | 59 | 94 | |
| Carboplatin | 42 | 67 | |
| Cisplatin | 19 | 30 | |
| Gemcitabine | 34 | 54 | |
| Paclitaxel | 24 | 38 | |
| Docetaxel | 19 | 30 | |
| Pemetrexed | 6 | 10 | |
| EGFR inhibitor* | 21 | 33 | |
| Erlotinib | 12 | 19 | |
| Gefitinib | 10 | 16 | |
| Cetuximab | 2 | 3 | |
| Other | 9 | 14 | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NSCLC, non–small-cell lung cancer; NOS, not otherwise specified; EGFR, epidermal growth factor receptor.
*
Cetuximab, erlotinib, or gefitinib.